Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137789 | 0.92 | AKR1B1 (0.52) | ITGA4ITGB7CYP1A2SLC7A5TSHR | |
| SCHEMBL23314140 | 0.91 | GABRA1 (0.44) | ITGA4ITGB7CYP1A2SLC7A5F10 | |
| SCHEMBL25564330 | 0.91 | LOXL2 (0.47) | ITGA4ITGB7CYP1A2SLC7A5F10 | |
| SCHEMBL8936324 | 0.88 | CTBP2 (0.51) | ITGA4ITGB7CYP1A2CTBP2 | |
| SCHEMBL10137770 | 0.88 | CTBP2 (0.54) | ITGA4ITGB7CTBP2POLB | |
| SCHEMBL21649896 | 0.87 | PTGES (0.48) | ITGA4ITGB7 | |
| SCHEMBL10137783 | 0.87 | CTBP2 (0.54) | TSHRCTBP2 | |
| SCHEMBL10137784 | 0.87 | SLC1A1 (0.46) | F10TSHRCYP2C19 | |
| SCHEMBL12553242 | 0.87 | HDAC4 (0.44) | ITGA4ITGB7CYP1A2F10 | |
| SCHEMBL25862861 | 0.87 | MAOA (0.44) | ITGA4ITGB7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206963-A1 | COPOLYMER BLENDS | BIOME BIOPLASTICS LIMITED (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10689430-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | ITGA4 2895/4885ITGB7 1521/4885CYP1A2 3000/4885 |
| US-10689430-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | ITGA4 2895/4885ITGB7 1521/4885CYP1A2 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.